Analysts think so. Four covering CRDL have set price targets between
Moreover, debt-free CRDL is demonstrating that its drug can do what others can't- fight effectively against myopericardial diseases due to its anti-inflammatory and anti-fibrotic properties. In fact, those latter differences are also significant advantages compared to drugs developed by Big Pharma, including
Video Link: https://www.youtube.com/embed/LI6TeOzmIQM
Accelerating Through Phase II With Milestones In-Play
And they are on the right track by developing CardiolRx with anti-inflammatory and anti-fibrotic properties to treat particular cardiovascular diseases.
That success adds to the bullish proposition, knowing that milestones reached by CRDL can become catalysts to exploit a multi-billion dollar treatment market opportunity. Three are currently in play. The first relates to its Phase II Recurrent Pericarditis Study, with CRDL potentially announcing completed enrollment and interim analysis this year. That's not all. Speculation supports CRDL also initiating its Phase III program by year's end. If so, those who follow biotechs know that the valuation difference between a Phase II and III company can be substantial. The better news is that more than one trial may advance to late-stage.
Cardiol is also expected to complete enrollment and report topline data from its Phase II Acute Myocarditis Study. That one could also jump directly to Phase III based on its data supporting the need for this drug candidate to get to patients quickly. A third milestone relates to its advancing research for CRD-38, with the company expecting to complete IND-enabling (Investigational New Drug Application) studies, submit the IND, and initiate the Phase I Clinical Program.
Collaborations To Fight Recurrent Pericarditis
Here's something else to consider when appraising the CRDL value proposition. Unlike most go-it-alone microcap biotechs, CRDL is getting plenty of research help. The company has joined forces with world-class researchers and clinicians to better understand inflammation and fibrosis, drug development processes, and clinical trial protocols that can lead to expedited approvals. The list of collaborators comprises an enviable Who's Who list of heart disease research contributors, including
Invariably, that's helped facilitate progress, likely expediting Phase II studies that evaluated CardiolRx' tolerability, safety, and efficacy in patients with recurrent pericarditis. Pericarditis is the membrane inflammation surrounding the heart, which leads to fluid accumulation and pericardial thickening. It becomes recurrent if symptoms reappear after a symptom-free period of 4-6 weeks. The symptoms of pericarditis include chest pain, shortness of breath, and depression. Severe cases affect quality of life and physical activity abilities and can even lead to emergency department visits or hospitalizations. It touches many lives.
Pericarditis affects 38,000 Americans and leads to 18,000 hospitalizations annually. While bad enough, recurrent pericarditis is much worse, usually lasting anywhere from 4-6 years in difficult-to-treat cases. If granted FDA orphan and/or EMA approval, CardiolRx could, therefore, treat the patient throughout that entire treatment life-cycle, with revenues generated in the hundreds of thousands, not tens of dollars, per complete treatment. Moreover, CardiolRx can fill an unmet medical need for an oral drug that treats patients intolerant to therapy, colchicine resistant, or corticosteroid dependent.
Current pharmacotherapy solutions include NSAIDs or aspirin that don't contain colchicine and corticosteroids for patients with continued recurrence. One FDA-approved therapy is over
The Battle Against Acute Myocarditis
Battling Acute Myocarditis can be equally devastating to a patient's health and finances. Acute Myocarditis is an inflammatory heart muscle condition, often resulting from a viral infection. Symptoms include chest pain, impaired heart function, arrhythmia, and conduction disturbances. Most troubling about this condition is that it generally affects young adults from adolescence to mid-thirties. Still, while the affliction age is wide, most cases are recorded in patients in their early twenties, with acute and fulminant heart failure occurring in young adults. In fact, Acute Myocarditis is a leading cause of sudden cardiac death in people under 35 years of age. Athletes, despite being in top physical condition, have died from this. Thus, diet and exercise won't stop an attack. But a better drug can save lives.
Here's more excellent news. CardiolRx can also earn FDA orphan drug and EMA approvals for treating acute myocarditis. It, too, takes a personal and financial toll. An estimated 46,000 Americans are impacted by acute myocarditis annually. Hospitalizations can be upwards of 7 days and tally
Thus, a treatment to address problems early on would benefit patients significantly. As importantly, an approved drug from CRDL could fill a clear unmet medical need for a well-tolerated therapeutic that targets myocardial inflammation. There are no FDA-approved therapies for acute myocarditis, only guideline-directed therapies and management. These therapies include decreasing cardiac workload, reducing congestion, and improving how blood flows through arteries and veins and the forces that affect a patient's blood flow. Currently, corticosteroids are used to treat inflammation. However, the issue with those drugs is that they are widely intolerable, can have adverse side effects, and have an inconsistent record of optimal dosing.
A Rally Likely To Continue
In simplest terms, CRDL is timely to a massive market and treatment opportunity. Better still, they have excellent candidates with intrinsic strength and inherent potential to change the treatment landscape for specific cardiac diseases. That's needed. It's estimated that in
Thus, the YTD rally in CRDL is more than warranted; it's deserved. By potentially filling significant unmet medical needs, CRLD is in the sweet spot of opportunity from drug candidates that can earn more than a prescriber's interest; they can earn front-line standard-of-care designations. If so, the current share price could be a springboard, not a platform for higher prices. In fact, being the best drug standing in a sector worth billions, anything less than an exponential increase in the CRLD share price would be, in a word, disappointing.
Disclaimers:
The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.
Media Contact
Company
Contact Person: Editorial Dept.
Email: info@hawkpointmedia.com
Country:
Website: https://hawkpointmedia.com/
.
(C) 2023 M2 COMMUNICATIONS, source